[HTML][HTML] New clinical trial design in precision medicine: discovery, development and direction
XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …
certain disease are complex and different from each other. Due to the underestimation of the …
The genomic landscape of the immune system in lung cancer: present insights and continuing investigations
M Roshan-Zamir, A Khademolhosseini… - Frontiers in …, 2024 - frontiersin.org
Lung cancer is one of the most prevalent malignancies worldwide, contributing to over a
million cancer-related deaths annually. Despite extensive research investigating the genetic …
million cancer-related deaths annually. Despite extensive research investigating the genetic …
[HTML][HTML] Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies
Y He, F Gong, T Jin, Q Liu, H Fang, Y Chen, G Wang… - Biomolecules, 2023 - mdpi.com
Cold atmospheric plasma (CAP) generates abundant reactive oxygen and nitrogen species
(ROS and RNS, respectively) which can induce apoptosis, necrosis, and other biological …
(ROS and RNS, respectively) which can induce apoptosis, necrosis, and other biological …
[HTML][HTML] Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2
Y Yuan, L Hao, JS Huang, FY Zhao, YH Ju… - Cell Death & …, 2024 - nature.com
Lung cancer stands as the leading cause of mortality among all types of tumors, with over
40% of cases being lung adenocarcinoma (LUAD). Family with sequence similarity 83 …
40% of cases being lung adenocarcinoma (LUAD). Family with sequence similarity 83 …
[HTML][HTML] Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
Y Han, Y Xiong, T Lu, R Chen, Y Liu, H Tang… - Frontiers in …, 2023 - frontiersin.org
Background HER2-targeted therapy provides survival benefits to HER2-mutant non-small
cell lung cancer (NSCLC). A better understanding of the clinical and genomic …
cell lung cancer (NSCLC). A better understanding of the clinical and genomic …
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study
J Chen, C Xu, Q Wang, J Lv, W Lu, Y Zhang, Y Yao… - Lung Cancer, 2023 - Elsevier
Background Although the treatment of ERBB2-altered non-small cell lung cancer (NSCLC)
has been studied for many years, there are no comprehensive studies to evaluate the …
has been studied for many years, there are no comprehensive studies to evaluate the …